Form Approved OMB No. 0920-1282 Expiration Date: 1/31/2023

# **STD PCHD Performance Measurement**

Year 1

Project Area:	Select Project Area]
Period of Performance:	/1/2019 - 12/31/2019
Submission Date:	
If other reporting period, or if varies by performance measure, describe:	Free Text]
Other comments related to this submission (optional):	Free Text]

Click the navigation bar or a tab at the bottom of the workbook to jump to the corresponding worksheet.

### Instructions:

You may use this template to prepare a STD PCHD Performance Measures for DSTDP. Please refer to the supplemental guidance document for more information. Complete each tab in this workbook, except for those labeled "optional."

Applicants will complete and submit performance measures each year, depending on approval from OMB.

If you need technical support at any time, please send an email with a detailed description of your need to the following address:

## STD\_PCHD@cdc.gov

## Notes on Data Entry:

All light yellow cells are available for user input. White cells are auto-calculated based on information provided in the yellow cells.

Drop-down menus are included in all worksheets, and should be identifiable through a downward arrow that appears when you select it.

The core performance measures in each worksheet are bolded. Measures that are auto-calcuated but not considered core performance measures are italicized (not bolded).

## Saving and Submitting Your Work:

Click "File" from the ribbon above and then "Save" from the menu. If this is your first time saving this document, you will be prompted to choose a location for where this file will be saved. **Please save this file as "[ProjectAreaName]\_Performance.Measures.2019\_yy-mm-dd" and as an .xlsm version**. (Note: you will see a warning message reminding you that if you change the format of the document, you may lose some of the functionality. Click "Ok" and save the file in your preferred location.)

<u>C</u>lick "File" from the ribbon above and then "Save As" from the menu or use the button below. Choose the .xls or .xlsx file type from the "Save as type" drop-down menu. You will see a warning sign that says "The following features cannot be saved in macro-free workbooks: VB project". Click "Yes" to save the file as a .xls or .xlsx file type. You will still be able to edit light yellow cells, but a few features from this workbook will no longer be available.

To submit this document, attach the file ending in .xls or .xlsx as a Grant Note in GrantSolutions.

#### **Relevant Links:**

To access the series of Technical Assistance Notes for the PS19-1901 STD PCHD strategies, click here: <u>PS19-1901 STD PCHD Technical Assistance Notes</u> To find general information on using Microsoft Excel, click here: <u>Microsoft Excel Basics</u>

#### **Reporting Burden**

This information is collected under the authority of the Public Health Service Act, Section 301, "Research and Investigation," (42 U.S.C. 241); and Sections 304, 306 and 308(d) which discuss authority to maintain data and provide assurances of confidentiality for health research and related activities (42 U.S.C. 242 b, k, and m(d)). This information is also being collected in conjunction with the provisions of the Government Paperwork Elimination Act and the Paperwork Reduction Act (PRA). This information will only be used by the Centers for Disease Control and Prevention (CDC) staff to monitor recipient's progress under cooperative agreement PS19-1901 STD PCHD.

Public reporting burden of this collection of information is estimated to average 30 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-1282)

	Surveillance		
Line No.	Enhanced GC surveillance	Data Fields	
a_1	Did your project area complete follow-up of any GC cases for any enhanced GC surveillance purposes (Strategy 2b) in the reporting period?		drop dow menu
a_2	If yes ( <b>a_1</b> ), what geographic area(s) were included in the enhanced GC surveillance activities?		text field
a_3	Out of 12 months in the reporting period, what dates did your project area conduct enhanced GC surveillance?		
a_4	Total # of GC cases that were reported in that time period (a_3) and in that geographic area (a_2)		
a_5	Among those <b>(a_4)</b> , <b>#</b> of GC cases that were randomly selected for enhanced surveillance		
a_6	Among those <b>(a_5)</b> , # that received provider and/or patient follow-up for enhanced surveillance		
a_7	Among GC cases sampled for enhanced surveillance follow- up, % that received provider and/or patient follow-up		auto- calculated
a_8	Low or poor data quality?		drop dow menu
a_9	Any data limitations, including reasons unable to report		text field
	Pregnancy Ascertainment		
a_10	Total # of female syphilis cases (all stages)		
a_11	Total # of female syphilis cases (all stages) with pregnancy status documented as "Yes, pregnant"		
a_12	Total # of female syphilis cases (all stages) with pregnancy status documented as "No, not pregnant"		
a_13	Total # of female syphilis cases (all stages) with pregnancy status documented as "Unknown" or "Missing"		
a_14	Proportion of female syphilis cases (all stages) that had pregnancy status documented as "Yes, pregnant" or "No, not pregnant"		auto- calculatec
a_15	Is your surveillance and/or case management system able to document <u>when</u> pregnancy status was obtained?		drop dow menu
a_16	If yes ( <b>a_15</b> ): Total <b>#</b> of female syphilis cases (all stages) with pregnancy status documented as "Yes, pregnant" or "No, not		
_	pregnant" within 14 days of specimen collection		
_ a_17	Among all female syphilis cases (all stages), % with pregnancy status documented as "Yes, pregnant" or "No, not pregnant" within 14 days of specimen collection	#DIV/01	auto- calculated
	Among all female syphilis cases (all stages), % with pregnancy status documented as "Yes, pregnant" or "No, not pregnant"	#DIV/0!	

	Congenital Syphilis		
Line No.	Potential cases averted	Data Fields	
b_1	Total # of females with syphilis (all stages) in the project area in the reporting period		
b_2	Total # of pregnant females with syphilis (all stages)		
b_3	% of total female syphilis cases that were pregnant	#DIV/0!	auto-calculated
b_4	Total # of reported congenital syphilis cases and stillbirths		
b_5	Total # of potential congenital syphilis cases averted	0.00	auto-calculated
b_6	Among all potential congenital syphilis cases, % averted	#DIV/0!	auto-calculated
b_7	Low or poor data quality?		drop down menu
b_8	Any data limitations, including reasons unable to report		text field

	Outbreak response		
Line No.	Disease Investigation and Intervention	Data Fields	1
	Activation of STD outbreak respo	nse plan	1
c_1	Total # of times that the outbreak plan was initiated for syphilis by the project area in the reporting period		
c_2	Total # of times that the outbreak plan was initiated for GC in the reporting period		
c_3	Total # of times that the outbreak plan was initiated for another STD in the reporting period		
c_4	Total # of times that the outbreak plan was initiated for an STD	0	auto- calculated
	Staff assignments to assist other o	utbreaks	
c_5	Total # of the STD program staff who were given temporary, formal assignments to assist with outbreaks with HIV, Hepatitis, or TB, during the reporting period		
c_6	Total # of STD program staff who were given temporary, formal assignments to assist with outbreaks with other conditions (not STD, HIV, Hepatitis, TB) during the reporting period		
c_7	Total # of STD staff deployed for non-STD outbreaks	0	auto- calculated
c_8	Total # of outbreak responses (HIV, Hepatitis, TB, or other conditions) for which those staff were formally assigned to assist.		
	Data quality		
c_9	Low or poor data quality?		drop down menu
c_10	Any data limitations, including reasons unable to report		text field

		Early Syphilis Cases: Dise	ase Investigation and I	ntervention			
Line No.	Key Populations:	Pregnant females under age 45	Other females under age 45	Men with only female partners (MSW)	Men with male partners (MSM and MSMW)	Sum Totals (auto- calculated)	
d_1	Total # of early syphilis cases by the project area in the reporting period					0	
d_2	Total # of cases initiated					0	1
d_3	Total # of cases interviewed					0	
d_4	Interview Rate	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		auto-ca
1_5	Total # of contacts (partners) initiated for partner services					0	
d_6	Contact Index	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		auto-ca
d_7	Total # of contacts examined (tested) within 30 days before or after the index patient's initial specimen collection (Dispo A, B, C, D, E, F, Z)					0	
8_b	New Exam Rate	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		auto-ca
d_9	Total <b>#</b> of contacts previously treated ( <u>Dispo E</u> ) within 30 days before or after the index patient's initial specimen collection					0	
d_10	Total <b>#</b> of contacts preventively treated ( <u>Dispo A</u> ) within 30 days before or after the index patient's initial specimen collection					0	
d_11	Total <b>#</b> of contacts preventively treated ( <u>Dispo Z</u> ) within 30 days before or after the index patient's initial specimen collection					0	
d_12	Total <b>#</b> of contacts brought to Tx for new syphilis infection ( <u>Dispo C</u> ) within 30 days after the index patient's initial specimen collection					0	
d_13	Treatment Index	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		auto-ca
d_14	Total # of cases w/at least 1 contact treated for syphilis (Dispo A, C, E, Z) within 30 days before or after the index patient's initial specimen collection					0	
d_15	Disease intervention rate	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		auto-ca
d_16	Total number of contacts (partners) brought to treatment	0	0	0	0	0	auto-ca
d_17	Total number of new cases of syphilis found through partner services	0	0	0	0	0.00	auto-ca
1_18	Low or poor data quality?						drop d
d_19	Any data limitations, including reasons unable to report						text fie

Line No	STD -related HIV Prevention in Disease Investigation		Syphilis Cases, by <b>j</b>	priority population		MSM GC Cases (If any investigated)	
e_1		Pregnant females under age 45 with early syphilis	Other females under age 45 with early syphilis	Men with only female partners (MSW) with early syphilis		Men with male partners (MSM and MSMW) with GC cases only	
e_2	Total # of cases in the project area in the reporting period	0	0	0	0		prepopulated sheets D and
e_3	Total # of cases initiated	0	0	0	0		prepopulate sheets D and
e_4	Total # of cases interviewed	0	0	0	0		prepopulate sheets D and
e_5	Of interviewed, # known to be living with HIV at the time of syphilis (of GC) diagnosis						
e_6	Of interviewed, # newly-diagnosed with HIV within 30 days of syphilis (or GC) diagnosis						
e_7	Of syphilis (or GC) cases newly diagnosed with HIV, # linked to HIV care within 30 days of new HIV diagnosis						
e_8	Of interviewed, # referred for PrEP within 30 days of syphilis (or GC) diagnosis						
2_9	Among interviewed, (known) HIV coinfection rate	0	#DIV/0!	0	0	#DIV/0!	
e_10	Among interviewed syphilis or GC cases (and not known to be HIV+), % newly-diagnosed with HIV within 30 days of syphilis (or GC) diagnosis	0	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	
e_11	Low or poor data quality						drop down
_12	Any data limitations, including reasons unable to report						text field
e_13	Among interviewed and newly diagnosed with HIV, % linked to HIV care within 30 days of new HIV diagnosis	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	
e_14	Low or poor data quality?						drop down i
_15	Any data limitations, including reasons unable to report						text field
e_16	Among interviewed (and not known to be HIV+), % referred for PrEP within 30 days of syphilis (or GC) diagnosis	0	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	
e_17	Low or poor data quality?				·	·	drop down
e_18	Any data limitations, including reasons unable to report						text field

Treatment				
Line No.	Recommended Treatment for syphilis	Data Fields		
f_1	Total # of early syphilis (ES) cases in the project area in the reporting period			
f_2	Total # of early syphilis cases missing data on medication		_	
f_3	Total # of early syphilis cases missing data on medication AND date of treatment or date of specimen collection (unable to calculate timeliness of treatment)			
f_4	% of early syphilis cases missing documentation of medication	#DIV/0!	auto calculatec	
f_5	% of early syphilis cases missing data to calculate timely treatment AND documentation of medication	#DIV/0!	auto calculatec	
f_6	Total # of early syphilis cases documented as having been prescribed/received BPG within 14 days of date of specimen collection		-	
f_7	Among early syphilis cases, % treated by BPG within 14 days of specimen collection	#DIV/0!		
f_8	Low or poor data quality?		drop dow menu	
f_9	Any data limitations, including reasons unable to report		text	
	Recommended Treatment for Gonorrhea			
f_10	For this measure, is the project area reporting on all cases or a random sample of cases, based on enhanced GC surveillance? If neither, explain below in Data Notes (g_21)		drop dowi	
f_11	Total # of GC cases reported in the reporting period (Overall or in random sample)			
f_12	Total # of GC cases missing data on medication (among all or among random sample)			
f_13	Total # of GC cases missing data on medication AND date of treatment or date of specimen collection(among all or among random sample)			
f_14	% of GC cases missing documentation of medication (among all or among random sample)	#DIV/0!	auto calculated	
f_15	% of GC cases missing data to calculate timely treatment AND documentation of medication (among all or among random sample)	#DIV/0!	auto calculated	
f_16	Total <b>#</b> of GC cases with recommended medication (in 2019: <u>dual therapy)</u> documented (among all or among random sample)			
f_17	Total <b>#</b> of GC cases with recommended medication (in 2019: <u>dual therapy)</u> documented as having been prescribed/received within 14 days of date of specimen collection (among all or among random sample)			
f_18	Among all GC cases, % with recommended medication documented, per CDC guidance (among all or among random sample)	#DIV/0!	auto calculated	

f_19	Among all GC cases, % with recommended medication documented within 14 days of the date of specimen collection, per CDC guidance (among all or among random sample)	auto calculated
f_20	Low or poor data quality?	drop down menu
f_21	Any data limitations, including reasons unable to report	text

	General General	Description of Safety Net Assistance (SNA)		
Line No.	Descr	iption	Data Fields	1
sna_1	Approximately what % of the STD PCHD budget did the project area devote to safety net assistance in the reporting period?			all drop down n unless noted as "text"
sna_2		Adolescents/young adults		1
sna_3	Did the project area specifically focus the safety net assistance	MSM		
sna_4	owards any of the following demographic groups? (select all	Pregnant women		
sna_5	that apply)	No, none of these groups were specifically focused on (though they may have benefited)		
sna_6		They met a certain threshold for positivity for testing		
sna_7		They met a certain threshold for STD disease morbidity or a certain STD case count or rate		
sna_8	What were the main formal criteria used for selecting which	They served under/uninsured populations		
sna_9	providers or organizations were eligible to access the safety net assistance (SNA) or were funded for SNA? (select all that apply)	They served other priority populations or geographic areas in need of subsidized services		
sna_10		They had a track record of effective partnership with us		1
sna_11		I'm not sure/don't know		
sna_12		Other: (please write answer below in sna_45 text box)		
sna_13		CT/GC urine testing/screening		
sna_14		CT/GC extragenital testing/screening		
sna_15	Which STD clinical prevention services did the safety net	CT/GC treatment, including EPT		
sna_16	assistance support? Select all that apply.	Syphilis testing/screening		4
sna_17	-	Syphilis treatment		4
sna_18		Other STD clinical preventive service: (please write answer below in sna_45 text box)		
sna_19		STD specialty care clinics		
sna_20	-	Local health department clinics (general)		
sna_21	-	Family planning/ reproductive health clinics		4
sna_22	-	Maternal and child health programs		4
sna_23	-	HIV prevention or care clinics		4
sna_24		Behavioral or mental health agencies, including drug treatment		
sna_25	Which types of providers were funded directly by the project area for safety net assistance (SNA) or were given the	Federally-qualified health centers (FQHC) or other community health centers		
sna_28	opportunity to take advantage of the SNA during the reporting period? Select all that apply.			
sna_29		School-based, college, or university health centers		4
sna_30	-	Tribal or Indian Health Service health care centers		4
		Other non-profit, private health care providers or organizations (e.g., CBOs)		
		Other private health care providers or organizations		
sna_31		Others not listed: (please write answer below in sna_45 text box)		
sna_32		We don't know/ aren't sure		1

		Often found in Contract bu	dget line:
sna_33		(A) Direct contracts or subgrants with health care organizations or providers for safety net assistance only	
sna_34		(B) Direct contracts or subgrants with health care organizations or providers for various services that include safety net assistance	
sna_35	What are the primary mechanisms through which the project area provided the safety net assistance (SNA)? Select all that	(C) Direct contracts or subgrants with lab(s) (public or private) to conduct testing for certain providers	
	apply.	Often found in Supplies, Other,	or Personnel:
sna_36		(D) Purchase of test kits or treatment/EPT, which are then distributed or allocated to certain providers by us	
sna_37		(E) Support all/part of the salary of lab(s) staff to conduct testing for certain providers or types of tests	
sna_38		(F) Other: (please write answer below in sna_45 text box)	
sna_39		Yes, we added state (or local) project area funds (e.g. STD, general)	
sna_40	Did the project area combine the STD PCHD safety net	Yes, we added federal funds (e.g. HIV, Title X, HRSA)	
sna_41	assistance with funding from other sources, to fund those contracts/ subgrants (A-C), to make those purchases (D), or	Yes, we added other funding sources	
sna_42	support those staff (E)? Select all that apply.	No, STD PCHD was the only funding we put into those contracts/subgrants/purchases	
sna_43		Don't know/ too unsure to answer	
	(Optional) Please provide any other information you would like worksheet for which you selected "Other":	to add about your approach to providing SNA in the reporting p	eriod, or answers to question on this
sna_44		Often found in Contract bu	daat line.
	-	(A) Direct contracts or subgrants with health care	
sna_45		organizations or providers for safety net assistance only	
sna_46		(B) Direct contracts or subgrants with health care organizations or providers for various services that include safety net assistance	
sna_47		(C) Direct contracts or subgrants with lab(s) (public or private)	
511a_+/	For which parts of your safety net assistance do you have data	to conduct testing for certain providers	
	For which parts of your safety net assistance do you have data on tests conducted, test results, or treatment purchased?	to conduct testing for certain providers Often found in Supplies, Other,	or Personnel:
sna_47			or Personnel:
		Often found in Supplies, Other, (D) Purchase of test kits or treatment/EPT, which are then	or Personnel:
sna_48		Often found in Supplies, Other, (D) Purchase of test kits or treatment/EPT, which are then distributed or allocated to certain providers by us (E) Support all/part of the salary of lab(s) staff to conduct	or Personnel:
sna_48	on tests conducted, test results, or treatment purchased?	Often found in Supplies, Other, (D) Purchase of test kits or treatment/EPT, which are then distributed or allocated to certain providers by us (E) Support all/part of the salary of lab(s) staff to conduct testing for certain providers or types of tests	

Line No.	Descripton	erchanism selected in Admin_SNA_o Data Fields	Data Fields	Data Fields
	•	Data Fields	Data Fields	Data Fields
sna_52	Which mechanism does the following refer to?			
sna_53	Which of the following groups of clients does the following testing data refer to?		[Select from Dropdown]	
	How many tests were conducted?	Syphilis tests performed	GC tests performed	CT tests performed
sna_54	Total tests conducted			
sna_55	All Males			
sna_56	Males, 15-24 years			
sna_57	Males, 25-44			
sna_58	Males, 45+			
sna_59	All Females			
sna_60	Females, 15-24 years			
sna_61	Females, 25-44			
sna_62	Females, 45+			
	Of those tests, how many were positive or reactive?	Positive Syphilis tests	Positive GC tests	Positive CT tests
sna_63	Total positive or reactive tests			
sna_64	All Males			
sna_65	Males, 15-24 years			
sna_66	Males, 25-44			
sna_67	Males, 45+			
sna_68	All Females			
sna_69	Females, 15-24			
sna_70	Females, 25-44			
sna_71	Females, 45+			
	Positivity	Among Syphilis tests performed	Among GC tests performed	Among CT tests performed
sna_72	Total tests	#DIV/0!	#DIV/0!	#DIV/0!
sna_73	All Males	#DIV/0!	#DIV/0!	#DIV/0!
sna_74	Males, 15-24 years	#DIV/0!	#DIV/0!	#DIV/0!
sna_75	Males, 25-44	#DIV/0!	#DIV/0!	#DIV/0!
sna_76	Males, 45+	#DIV/0!	#DIV/0!	#DIV/0!
sna_77	All Females	#DIV/0!	#DIV/0!	#DIV/0!
sna_78	Females, 15-24	#DIV/0!	#DIV/0!	#DIV/0!
sna_79	Females, 25-44	#DIV/0!	#DIV/0!	#DIV/0!
sna_80	Females, 45+	#DIV/0!	#DIV/0!	#DIV/0!
	Treatment medication (if any purchased with STD PCHD safety net assistance)	Syphilis medication	GC medication	CT medication
sna_81	Total medication units purchased in reporting period. Please write in units tracked by your program, e.g. "X# BIC injections" or "Y# pills" or "Z# patient TX packs."			
	If you are unable to provide the above information on the tes	ts performed, test results, or treatme	ent purchases attributable to STD PCI	HD, please explain why not:
sna_82				
	(Optional) Please provide any other information you would lik reporting period:	e to add about the treatment or pati	ent testing data that you provided o	n the safety net assistance in the
sna_83				

USE ONLY IF MORE THAN 1 MECHANISM IS BEING REPORTED ON

	· · · · · · · · · · · · · · · · · · ·	rchanism selected in Admin_SNA_ov		
ine No.	Descripton	Data Fields	Data Fields	Data Fields
sna_52	Which mechanism does the following refer to?			
sna_53	Which of the following groups of clients does the following testing data refer to?		[Select from Dropdown]	
	How many tests were conducted?	Syphilis tests performed	GC tests performed	CT tests performed
sna_54	Total tests conducted			
sna_55	All Males			
sna_56	Males, 15-24 years			
sna_57	Males, 25-44			
sna_58	Males, 45+			
sna_59	All Females			
sna_60	Females, 15-24 years			
sna_61	Females, 25-44			
sna_62	Females, 45+			
	Of those tests, how many were positive or reactive?	Positive Syphilis tests	Positive GC tests	Positive CT tests
sna_63	Total positive or reactive tests			
sna_64	All Males			
sna_65	Males, 15-24 years			
sna_66	Males, 25-44			
sna_67	Males, 45+			
sna_68	All Females			
sna_69	Females, 15-24			
sna_70	Females, 25-44			
sna_71	Females, 45+			
	Positivity	Among Syphilis tests performed	Among GC tests performed	Among CT tests performed
sna_72	Total tests	#DIV/0!	#DIV/0!	#DIV/0!
sna_73	All Males	#DIV/0!	#DIV/0!	#DIV/0!
sna_74	Males, 15-24 years	#DIV/0!	#DIV/0!	#DIV/0!
sna_75	Males, 25-44	#DIV/0!	#DIV/0!	#DIV/0!
sna_76	Males, 45+	#DIV/0!	#DIV/0!	#DIV/0!
sna_77	All Females	#DIV/0!	#DIV/0!	#DIV/0!
sna_78	Females, 15-24	#DIV/0!	#DIV/0!	#DIV/0!
sna_79	Females, 25-44	#DIV/0!	#DIV/0!	#DIV/0!
sna_80	Females, 45+	#DIV/0!	#DIV/0!	#DIV/0!
	Treatment medication (if any purchased with STD PCHD safety net assistance)	Syphilis medication	GC medication	CT medication
sna_81	Total medication units purchased in reporting period. Please write in units tracked by your program, e.g. "X# BIC injections" or "Y# pills" or "Z# patient TX packs."			
	If you are unable to provide the above information on the tests	performed, test results, or treatmen	t purchases attributable to STD PCHI	), please explain why not:
sna_82				
	(Optional) Please provide any other information you would like reporting period:	to add about the treatment or patie	nt testing data that you provided on	the safety net assistance in the
sna_83				

USE ONLY IF MORE THAN 2 MECHANISMS ARE BEING REPORTED ON

		erchanism selected in Admin_SNA_o		
ine No.	Descripton	Data Fields	Data Fields	Data Fields
sna_52	Which mechanism does the following refer to?			
sna_53	Which of the following groups of clients does the following testing data refer to?	[Select from Dropdown]		
	How many tests were conducted?	Syphilis tests performed	GC tests performed	CT tests performed
sna_54	Total tests conducted			
sna_55	All Males			
sna_56	Males, 15-24 years			
sna_57	Males, 25-44			
sna_58	Males, 45+			
sna_59	All Females			
sna_60	Females, 15-24 years			
sna_61	Females, 25-44			
sna_62	Females, 45+			
	Of those tests, how many were positive or reactive?	Positive Syphilis tests	Positive GC tests	Positive CT tests
sna_63	Total positive or reactive tests			
sna_64	All Males			
sna_65	Males, 15-24 years			
sna_66	Males, 25-44			
sna_67	Males, 45+			
sna_68	All Females			
sna_69	Females, 15-24			
sna_70	Females, 25-44			
sna_71	Females, 45+			
	Positivity	Among Syphilis tests performed	Among GC tests performed	Among CT tests performed
sna_72	Total tests	#DIV/0!	#DIV/0!	#DIV/0!
sna_73	All Males	#DIV/0!	#DIV/0!	#DIV/0!
sna_74	Males, 15-24 years	#DIV/0!	#DIV/0!	#DIV/0!
sna_75	Males, 25-44	#DIV/0!	#DIV/0!	#DIV/0!
sna_76	Males, 45+	#DIV/0!	#DIV/0!	#DIV/0!
sna_77	All Females	#DIV/0!	#DIV/0!	#DIV/0!
sna_78	Females, 15-24	#DIV/0!	#DIV/0!	#DIV/0!
sna_79	Females, 25-44	#DIV/0!	#DIV/0!	#DIV/0!
sna_80	Females, 45+	#DIV/0!	#DIV/0!	#DIV/0!
	Treatment medication (if any purchased with STD PCHD safety net assistance)	Syphilis medication	GC medication	CT medication
sna_81	Total medication units purchased in reporting period. Please write in units tracked by your program, e.g. "X# BIC injections" or "Y# pills" or "Z# patient TX packs."			
	If you are unable to provide the above information on the tests performed, test results, or treatment purchases attributable to STD PCHD, please explain why not:			
sna_82				
	(Optional) Please provide any other information you would like to add about the treatment or patient testing data that you provided on the safety net assistance in the reporting period:			
sna_83				